Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

14.3%

4 terminated out of 28 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

11%

3 trials in Phase 3/4

Results Transparency

6%

1 of 18 completed with results

Key Signals

1 with results82% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (4)
Early P 1 (1)
P 1 (7)
P 2 (11)
P 3 (3)

Trial Status

Completed18
Unknown5
Terminated4
Withdrawn1

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (28)

Showing 20 of 20 trials
NCT00005884Phase 3CompletedPrimary

Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer

NCT00103246Phase 1Completed

Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides

NCT00021294Phase 2CompletedPrimary

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00005097Phase 2TerminatedPrimary

Green Tea Extract in Treating Patients With Actinic Keratosis

NCT00663910Early Phase 1TerminatedPrimary

Topical Aminolevulinic Acid in Patients With Nonmelanoma Skin Cancer

NCT00433485Phase 1Completed

Topical Sirolimus in Patients With Basal Cell Nevus Syndrome and in Healthy Participants

NCT00003611Not ApplicableCompletedPrimary

Acitretin in Preventing Skin Cancers in Patients With Previously Treated Skin Cancers Who Have Undergone Organ Transplantation

NCT00899132TerminatedPrimary

Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

NCT00099112CompletedPrimary

Effect of Solar-Simulated Ultraviolet Radiation on Gene Expression in Unprotected and Sunscreen-Protected Skin of Healthy Adults With Fitzpatrick Skin Type II

NCT00747903Phase 2UnknownPrimary

Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer

NCT00423397Phase 1UnknownPrimary

Gefitinib and PEG-Interferon Alfa-2a in Treating Patients With Unresectable or Metastatic Skin Cancer

NCT00391300Phase 1Unknown

Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions

NCT00295906Not ApplicableUnknown

Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control

NCT00002975Phase 2CompletedPrimary

Photodynamic Therapy in Treating Patients With Skin Cancer

NCT00066872Phase 3CompletedPrimary

Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer

NCT00023621Phase 2CompletedPrimary

Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome

NCT00021125Phase 3Completed

Radiation Therapy in Treating Patients With Head and Neck Cancer

NCT00025012Not ApplicableCompleted

Isotretinoin in Preventing Skin Cancer

NCT00079300Phase 1CompletedPrimary

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

NCT00025051Phase 2WithdrawnPrimary

Celecoxib in Preventing Skin Cancer

Scroll to load more

Research Network

Activity Timeline